Skip to content

GHRP-2 Dosage Guide: Protocols, Timing & How Much to Take (2026)

From Peptidepedia, the trusted peptide wiki.

Dosage Protocols

No FDA-approved dosing guidelines exist for GHRP-2. The following protocols are derived from clinical research and practitioner experience:

  • Standard range: 100 to 300 mcg per injection, administered subcutaneously one to three times daily
  • Saturation dose: Approximately 1 to 2 mcg/kg body weight per injection, beyond which additional GH release plateaus
  • Most common protocol: 100 to 200 mcg at bedtime, as this amplifies the natural nocturnal GH surge

Beginner Protocol

100 mcg once daily before bed, for 8 to 12 weeks. The bedtime dose is the single most important administration window because it coincides with the body's largest endogenous GH pulse.

Intermediate Protocol

150 to 200 mcg, two times daily (morning fasted and before bed), for 8 to 12 weeks. Adding a morning dose captures a second GH pulse opportunity while fasting insulin levels are low.

Advanced Protocol

200 to 300 mcg, two to three times daily, often combined with a GHRH analog such as CJC-1295 (no DAC) or Mod GRF 1-29, for 8 to 16 weeks. The synergy between GHRP-2 and a GHRH analog can amplify GH output two to three times beyond either peptide alone.

Cycling Recommendations

Cycling is recommended to maintain receptor sensitivity. A common approach is 8 to 12 weeks on followed by 4 to 8 weeks off. The peptide cycling guide covers protocols in more detail. Some practitioners use a 5-days-on, 2-days-off weekly schedule to reduce the risk of tachyphylaxis. A clinical study by Bowers et al. noted response attenuation after five consecutive days of GHRP-2 injections, reinforcing the rationale for periodic breaks.

Timing Considerations

GHRP-2 should be administered on an empty stomach, at least 30 minutes before eating or two or more hours after a meal. Elevated blood glucose and insulin significantly blunt the GH response. For the same reason, high-glycemic meals should be avoided around dosing windows.

Frequently Asked Questions

GHRP-2 produces stronger peak GH release but is less selective. Ipamorelin does not meaningfully raise cortisol, ACTH, or prolactin even at very high doses, whereas GHRP-2 causes moderate elevations in all three. Ipamorelin is chosen for cleanliness; GHRP-2 is chosen for raw GH output.

The most commonly cited dose is 100 to 300 mcg per injection administered subcutaneously, one to three times daily. A single 100 mcg dose at bedtime is a typical starting point, with users titrating upward based on response and tolerance.

Common side effects include increased appetite, flushing, transient drowsiness, water retention, and mild elevations in cortisol and prolactin. These effects are generally dose-dependent and less pronounced than with GHRP-6. Serious adverse events are rare in published clinical data.

By peak GH output, GHRP-2 is generally considered the most potent of the traditional GHRPs (GHRP-1, GHRP-2, GHRP-6, hexarelin). A study by Arvat et al. (1997) showed GHRP-2 produced GH responses exceeding those of maximal-dose GHRH when administered intravenously. However, hexarelin is comparable in potency with a slightly different side effect profile.

GHRP-2 is used off-label in anti-aging protocols to restore more youthful GH pulsatility. Elevated GH and IGF-1 levels are associated with improved skin quality, body composition, sleep, and recovery. Long-term safety data for this specific application is limited, and it remains unapproved for this use.

GHRP-2 is administered via subcutaneous injection on an empty stomach, at least 30 minutes before eating or 2 or more hours after a meal. The pre-bed dose is considered most important because it amplifies the natural nocturnal GH surge. Elevated blood glucose and insulin blunt the GH response.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Arvat E, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides. 1997;18(6):885-891.
  2. Mericq V, et al. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. Journal of Clinical Endocrinology & Metabolism. 1998;83(7):2355-2360.
  3. Berlanga-Acosta J, et al. Synthetic growth hormone-releasing peptides (GHRPs): a historical appraisal of the evidences supporting their cytoprotective effects. Clinical Medicine Insights: Cardiology. 2017;11:1179546817694558.
  4. Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25-37.
  5. Laferrere B, et al. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. Journal of Clinical Endocrinology & Metabolism. 2005;90(2):611-614.
  6. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
  7. Pihoker C, et al. Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature. Journal of Clinical Endocrinology & Metabolism. 1995;80(10):2987-2992.
  8. Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D. Drugs in R&D. 2004;5(4):236-239.
  9. Chihara K, et al. A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. Eur J Endocrinol. 2007;157(1):19-27.
  10. Thomas A, et al. Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by LC-MS/MS. Rapid Communications in Mass Spectrometry. 2010;24(11):1549-1557.
  11. World Anti-Doping Agency. The 2026 Prohibited List International Standard.

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”